U.S. Markets close in 3 hrs 22 mins

Hansen Medical to Exhibit Its Magellan(TM) Robotic System at 35th Annual Charing Cross International Symposium

MOUNTAIN VIEW, CA--(Marketwire - Apr 1, 2013) - Hansen Medical, Inc. ( NASDAQ : HNSN ), a global leader in intravascular robotics, today announced it will showcase its Magellan™ Robotic System at the 35th Annual Charing Cross International Symposium from April 6-9 in London. The Company will be exhibiting the Magellan Robotic System at Booth 628.

In addition, Professor Nick Cheshire, MD of St. Mary's Hospital, part of the Imperial College Healthcare NHS Trust in London, and Barry Katzen, MD, founder and Medical Director of the Baptist Cardiac & Vascular Institute (Baptist Hospital of Miami), will participate in a panel discussion titled, "Great Debate: Influence of Robotics and Simulators," during the "Carotid Challenges" session at 10:00 am on Tuesday, April 9. 

Hansen Medical will also be co-sponsoring a symposium with Philips Healthcare from 12:30 pm-3:30 pm on Monday, April 8 in the Green Learning Center, titled "Advanced Imaging in the Hybrid Operating Room." This symposium will feature Dr. Katzen who will discuss his clinical experiences with the Magellan System in a variety of interventional procedures.

Lastly, on Sunday, April 7 at 4:45 pm Professor Jean-Pierre Becquemin, MD of Creteil, France will present on his experiences with the Magellan System in a presentation titled, "Early Experiences with Intravascular Robotics."

"We are pleased that our Magellan Robotic System will be highlighted at Charing Cross, Europe's longest running and leading vascular symposium," said Bruce Barclay, President and CEO of Hansen Medical. "The presentations featuring our technology will provide additional opportunities for clinicians to better understand the significant clinical and economic benefits, and real world medical utility, provided by the Magellan System. We are also excited to be co-hosting a symposium with our partner Philips for the second consecutive year. Since commencing the initial U.S. launch of the Magellan System last June, we have generated a large and growing pipeline of clinical interest in our robotic technology, and we look forward to further building on this momentum at Charing Cross."

"At St. Mary's, we have performed a breadth of complex endovascular procedures with the Magellan Robotic System in the past year," said Professor Cheshire. "Charing Cross, being the premier European endovascular event, affords us the opportunity to discuss the clinical benefits we're seeing through the implementation of intravascular robotics."

About the Magellan™ Robotic System

Hansen Medical's Magellan Robotic System is based upon the flexible robotic technology incorporated in the Sensei-X® Robotic Catheter System currently sold in the U.S. and Europe, which has been used in excess of 10,000 patients, but includes a number of key enhancements. In particular, the Magellan Robotic System:

  • Provides solid catheter stability for placement of therapeutic devices.
  • Is designed to enable predictable procedure times and increased case throughput.
  • Allows for independent, individual robotic control of the distal tips of both the outer sheath and the inner leader catheter, as well as robotic manipulation of standard guidewires.
  • Is designed to allow for sufficient extension inside the body to access hard to reach peripheral anatomy.
  • Preserves the open architecture featured in the Sensei System to allow for the subsequent use of many 6F therapeutic devices on the market today.
  • Is designed to potentially reduce physician radiation exposure and fatigue by employing a remote physician workstation.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, is the global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits of our Magellan Robotic System for hospitals, patients and physicians, expectations of shipments and installations of our robotic systems, catheter sales, and procedures, expectations of gross margins and operating expenses for 2013, the sufficiency of the company's cash resources for supporting the Company's operations, expected efficiencies from cost saving initiatives, and the anticipated timing of commercially launching a 6F vascular catheter. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; the commercial viability of our products in the vascular markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on March 18, 2013 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.